TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34223388

Group type: EXPERIMENTAL
Intervention: Point-of-care naloxone distribution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Referral to an existing program
Number of subjects: 30
Study: 34223403

Group type: EXPERIMENTAL
Intervention: Glucose metabolism via glycolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxidative pentose phosphate pathway (oxPPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose feeding amino acid synthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactate exchange via monocarboxylic transporters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose metabolism
Number of subjects: 0
Study: 34223402

Group type: EXPERIMENTAL
Intervention: RH5.1 recombinant protein vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RH5.1/AS01
Number of subjects: 0
Study: 34223516

Group type: EXPERIMENTAL
Intervention: Sedation practices
Number of subjects: 0
Study: 34223895

Group type: EXPERIMENTAL
Intervention: Metreleptin (recombinant leptin)
Number of subjects: 38
Study: 34224257

Group type: EXPERIMENTAL
Intervention: Surge index (severity-weighted measure of COVID-19 caseload)
Number of subjects: 144116

Group type: EXPERIMENTAL
Intervention: Surge index
Number of subjects: 144116
Study: 34224261

Group type: EXPERIMENTAL
Intervention: Infusion Centers (ICs)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Emergency Departments (EDs)
Number of subjects: 269
Study: 34224302

Group type: EXPERIMENTAL
Intervention: Loop ileostomy closure in a 23-h stay setting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard in-hospital stoma closure (historical control)
Number of subjects: 30
Study: 34224432

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with BPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPA alone or in combination with PEA or medical therapy
Number of subjects: 0
Study: 34224438

Group type: EXPERIMENTAL
Intervention: Stored slides
Number of subjects: 21

Group type: COMPARATOR
Intervention: Freshly cut slides
Number of subjects: 21
Study: 34224466

Group type: EXPERIMENTAL
Intervention: Patients with anxiety symptoms
Number of subjects: 12913

Group type: COMPARATOR
Intervention: Patients without anxiety symptoms
Number of subjects: 12913

Group type: EXPERIMENTAL
Intervention: Both groups (with and without anxiety)
Number of subjects: 12913
Study: 34224497

Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FM) patients
Number of subjects: 57

Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA) patients
Number of subjects: 57
Study: 34224500

Group type: EXPERIMENTAL
Intervention: In situ simulation training
Number of subjects: 15
Study: 34224572

Group type: EXPERIMENTAL
Intervention: FODMAP intake
Number of subjects: 109362

Group type: EXPERIMENTAL
Intervention: Total FODMAPs
Number of subjects: 109362

Group type: EXPERIMENTAL
Intervention: FODMAP consumption
Number of subjects: 109362
Study: 34224583

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 1906
Study: 34224668

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (2 doses)
Number of subjects: 885
Study: 34224674

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 1909
Study: 34224684

Group type: EXPERIMENTAL
Intervention: XC001 gene therapy
Number of subjects: 33
Study: 34225165

Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Emotional eating (mediating variable)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Perceived stress controlling for emotional eating
Number of subjects: 169
Study: 34225229

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 1076
Study: 34225320

Group type: EXPERIMENTAL
Intervention: Head moving condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Head immobile condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BCI participants
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clinical factors
Number of subjects: 18
Study: 34225348

Group type: EXPERIMENTAL
Intervention: LTOWB + CT
Number of subjects: 70

Group type: COMPARATOR
Intervention: CT only
Number of subjects: 70
Study: 34225496

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 710
Study: 34225735

Group type: EXPERIMENTAL
Intervention: Comprehensive Rehabilitation with autonomy recovery and multimodal exercise programmes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multimodal exercise programme
Number of subjects: 50
Study: 34225764

Group type: EXPERIMENTAL
Intervention: SENSory re-learning of the UPPer limb after stroke (SENSUPP)
Number of subjects: 0
Study: 34225817

Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care (CSC) services modifications during and after the COVID-19 crisis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with multi-level stakeholders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of OnTrackNY program data
Number of subjects: 0
Study: 34226183

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo-to-tofacitinib
Number of subjects: 0
Study: 34226208

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control county (not specified)
Number of subjects: 0
Study: 34226282

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic clamp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control saline infusion (SC)
Number of subjects: 0
Study: 34227124

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing starting at predicted maximum tolerated dose (MTD)
Number of subjects: 0
Study: 34227407

Group type: EXPERIMENTAL
Intervention: Angioplasty of iliac and femoropopliteal arteries
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Angioplasty of iliac, femoral, and crural arteries
Number of subjects: 411

Group type: COMPARATOR
Intervention: Diagnostic angiography
Number of subjects: 411
Study: 34227790

Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic and resistance training) for 12 weeks, twice weekly
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline evaluation
Number of subjects: 13
Study: 34227849

Group type: EXPERIMENTAL
Intervention: Referral processes to clinic-community partnership programs for childhood obesity treatment
Number of subjects: 0
Study: 34228090

Group type: EXPERIMENTAL
Intervention: RISE Model of resilience
Number of subjects: 36
Study: 34228679

Group type: EXPERIMENTAL
Intervention: Same-Day Surgery for Breast Cancer Patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Surgery Protocol
Number of subjects: 0
Study: 34228983

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study: 34228981

Group type: EXPERIMENTAL
Intervention: Near-focus narrow-band imaging (NF-NBI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: NF white-light endoscopy (NF-WLE)
Number of subjects: 100
Study: 34229125

Group type: COMPARATOR
Intervention: Lower arm blood pressure measurements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wrist blood pressure measurements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of lower arm vs upper arm blood pressure measurements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of upper arm vs wrist blood pressure measurements
Number of subjects: 100
Study: 34229186

Group type: EXPERIMENTAL
Intervention: Standardized antidepressant treatment protocol for 16 weeks
Number of subjects: 271
Study: 34229268

Group type: EXPERIMENTAL
Intervention: Single oral dose of 200 mg PM
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Three daily dose of 67 mg PM
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control for dietary intake
Number of subjects: 5
Study: 34229290

Group type: EXPERIMENTAL
Intervention: Hospitalization for acute exacerbations of COPD
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Outpatient exacerbations or no exacerbation
Number of subjects: 1219
Study: 34229325

Group type: EXPERIMENTAL
Intervention: Return of results (RoR) structures embedded in clinical care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Return of results (RoR) independent of clinical care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Reliance on clinical partnerships to facilitate RoR
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Accommodations for LRRP including social work referral and insurance enrollment assistance
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Support to access downstream treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Development of best practices and policies for managing RoR to LRRP
Number of subjects: 35
Study: 34229330

Group type: EXPERIMENTAL
Intervention: Overall TDR prevalence
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor resistance
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitor resistance
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Protease inhibitor resistance
Number of subjects: 573
Study: 34229580

Group type: EXPERIMENTAL
Intervention: PrEP use
Number of subjects: 20
Study: 34229705

Group type: EXPERIMENTAL
Intervention: Chinese version of the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 402
Study: 34229714

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control-based translational approach
Number of subjects: 20
Study: 34229929

Group type: EXPERIMENTAL
Intervention: Inpatient screening mammography
Number of subjects: 101
Study: 34230007

Group type: EXPERIMENTAL
Intervention: MDM2 inhibitor ALRN-6924
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic activation of p53
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDM2 inhibitors
Number of subjects: 0
Study: 34230011

Group type: EXPERIMENTAL
Intervention: Butyrylcholinesterase (BChE) activity measurement preoperatively and postoperatively
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Postoperative complication screening
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Point-of-care measurements for BChE
Number of subjects: 48
Study: 34230013

Group type: EXPERIMENTAL
Intervention: Age and geriatric and paraclinical parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional and nutritional parameters questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paraclinical parameters at ICU admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Univariate and multivariate logistic regressions
Number of subjects: 0
Study: 34230074

Group type: EXPERIMENTAL
Intervention: Imaging
Number of subjects: 0
Study: 34231041

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention to improve fatigue
Number of subjects: 44

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 44
Study: 34231126

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Interferon-β
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 240993

Group type: EXPERIMENTAL
Intervention: Natalizumab, Interferon-β, Dimethyl fumarate
Number of subjects: 240993
Study: 34231203

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions (including psychoeducation, cognitive behavioural therapy, group discussion, peer education, and art therapy)
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 1357

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1357
Study: 34231374

Group type: EXPERIMENTAL
Intervention: Two different stretching techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34231877

Group type: EXPERIMENTAL
Intervention: Anti-osteoporotic drugs (abaloparatide, alendronate, denosumab, raloxifene, teriparatide)
Number of subjects: 9164

Group type: EXPERIMENTAL
Intervention: Anti-osteoporotic drugs
Number of subjects: 9164
Study: 34231914

Group type: EXPERIMENTAL
Intervention: Opioid (morphine)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Opioid (opioid vs clonidine)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Opioid (opioid vs diazepam)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Opioid (opioid vs phenobarbital)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Opioid (morphine vs phenobarbital)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Opioid (morphine vs chlorpromazine)
Number of subjects: 1110
Study: 34232223

Group type: EXPERIMENTAL
Intervention: APO(a)LRx
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotinic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proprotein convertase subtilisin/kexin 9 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antisense oligonucleotide
Number of subjects: 0
Study: 34232291

Group type: EXPERIMENTAL
Intervention: Cer(d18:1/16:0)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Cer(d18:1/22:0)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Cer(d18:1/24:0)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: CERT-HBP (ceramide score)
Number of subjects: 920
Study: 34232493

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34232578

Group type: EXPERIMENTAL
Intervention: Treatment for postpartum depression
Number of subjects: 0
Study: 34232694

Group type: EXPERIMENTAL
Intervention: 0.3-mSv CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-Dose CT
Number of subjects: 0
Study: 34232841

Group type: EXPERIMENTAL
Intervention: Disc electrodes (DE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wire electrodes (WE)
Number of subjects: 29
Study: 34233252

Group type: EXPERIMENTAL
Intervention: Current smokers (n = 11,530)
Number of subjects: 50713

Group type: EXPERIMENTAL
Intervention: Current smokers (1 to 10 packs per year)
Number of subjects: 50713

Group type: EXPERIMENTAL
Intervention: Older group (smokers)
Number of subjects: 50713

Group type: EXPERIMENTAL
Intervention: Young middle age women (smokers)
Number of subjects: 50713

Group type: COMPARATOR
Intervention: Nonsmokers (n = 39,183)
Number of subjects: 50713
Study: 34233255

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 49
Study: 34233259

Group type: EXPERIMENTAL
Intervention: ALN-tumor radiomic signature for ALN status prediction
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Multiomic signature incorporating tumor and lymph node MRI radiomics, clinical and pathologic characteristics, and molecular subtypes
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Key radiomic features before and after neoadjuvant chemotherapy
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Association between MRI radiomics and tumor microenvironment features
Number of subjects: 1088
Study: 34233458

Group type: EXPERIMENTAL
Intervention: Glucose derivative treatment
Number of subjects: 0
Study: 34233538

Group type: EXPERIMENTAL
Intervention: Telehealth PTC classes
Number of subjects: 114

Group type: COMPARATOR
Intervention: In-person PTC classes
Number of subjects: 114
Study: 34233836

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 4320

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4320

Group type: COMPARATOR
Intervention: Gender (females vs males)
Number of subjects: 4320
Study: 34233941

Group type: EXPERIMENTAL
Intervention: Ketogenic/Intermittent-Fasting Diet (GLAD)
Number of subjects: 25
Study: 34233971

Group type: EXPERIMENTAL
Intervention: Simple trapeziectomy
Number of subjects: 37329

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 37329

Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 37329

Group type: EXPERIMENTAL
Intervention: Overall surgery
Number of subjects: 37329
Study: 34233992

Group type: EXPERIMENTAL
Intervention: Treatment pathways for knee OA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients' perspectives
Number of subjects: 0
Study: 34233996

Group type: EXPERIMENTAL
Intervention: OCT-derived vulnerable plaque characteristics of nonflow limiting, nonculprit lesions
Number of subjects: 438
Study: 34233999

Group type: EXPERIMENTAL
Intervention: Screening positive for common mental disorders (CMD)
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: Reporting suicidal ideation
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: Reporting perceptual symptoms
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: Suboptimal adherence associated with positive CMD screen
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: Positive CMD screens in women
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: Positive CMD screens in adults aged 40-49 years
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: Positive CMD screens in adults aged 50-59 years
Number of subjects: 3480
Study: 34234010

Group type: EXPERIMENTAL
Intervention: Weight-based high-flow nasal cannula (HFNC) protocol
Number of subjects: 0
Study: 34234673

Group type: EXPERIMENTAL
Intervention: IMMH-010
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YPD-29B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMMH-010 and YPD-29B
Number of subjects: 0
Study: 34235085

Group type: EXPERIMENTAL
Intervention: EphA2-redirected CAR T-cells (starting dosage 1×10)
Number of subjects: 3
Study: 34235186

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34235373

Group type: EXPERIMENTAL
Intervention: Workplace-based sugar-sweetened beverage (SSB) intervention over 10 months
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Workplace-based sugar-sweetened beverage (SSB) intervention
Number of subjects: 212
Study: 34236245

Group type: EXPERIMENTAL
Intervention: Upper limb hyperemia (verum group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo group)
Number of subjects: 80
Study: 34236298

Group type: EXPERIMENTAL
Intervention: Training in opioid treatment as peer recovery support service interventionists
Number of subjects: 0
Study: 34236338

Group type: EXPERIMENTAL
Intervention: Flexible endoscopic septotomy (FES)
Number of subjects: 256
Study: 34236339

Group type: EXPERIMENTAL
Intervention: Genetic risk loci for anxiety and PTSD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anxiety or PTSD genes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CTNND2
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Implicated systems
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to anxiety and PTSD
Number of subjects: 28
Study: 34236401

Group type: EXPERIMENTAL
Intervention: PLX9486 at 500 mg or less
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PLX9486 at 1000 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PLX9486 at 500 mg or less with sunitinib
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PLX9486 and sunitinib combination (25 or 37.5 mg)
Number of subjects: 39
Study: 34236437

Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (PDI)
Number of subjects: 74522

Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet index (hPDI)
Number of subjects: 74522

Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based diet index (uPDI)
Number of subjects: 74522
Study: 34236525

Group type: COMPARATOR
Intervention: Lying position (LyP) for 30 minutes daily during the first 7 days of hospitalization
Number of subjects: 24
Study: 34236570

Group type: EXPERIMENTAL
Intervention: Radiofrequency intravascular ultrasound (RF-IVUS)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison of RF-IVUS and OCT
Number of subjects: 103

Group type: COMPARATOR
Intervention: Reasons for discordance
Number of subjects: 103
Study: 34236995

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine (first dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine (second dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine (both doses)
Number of subjects: 19
Study: 34237031

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Selpercatinib combined with 131I therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Larotrectinib (in vitro)
Number of subjects: 106
Study: 34237102

Group type: EXPERIMENTAL
Intervention: Skydiving
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control visit
Number of subjects: 19
Study: 34237166

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 (ANGPT2)
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Angiopoietin-like 4 protein (ANGPTL4)
Number of subjects: 1853
Study: 34237347

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed on days 3, 7, and 14 after birth
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) score >10 at all 3 time points
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) alone
Number of subjects: 152
Study: 34238024

Group type: EXPERIMENTAL
Intervention: Pericardial adipose tissue (PAT)
Number of subjects: 2882

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 2882

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 2882
Study: 34238299

Group type: EXPERIMENTAL
Intervention: SD Biosensor Standard G6PD Test
Number of subjects: 45